07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

BioDelivery sales and marketing update

BioDelivery said an undisclosed managed care plan made Bunavail buprenorphine/naloxone its preferred treatment for opioid dependence. BioDelivery said the plan covers 10.5 million lives. Bunavail, a buprenorphine and naloxone polymer film formulated with BioDelivery’s BioErodible...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

BioDelivery sales and marketing update

BioDelivery said it is experiencing short-term supply constraints for Bunavail buprenorphine naloxone buccal film due to the introduction of a new source of a standard polymer by a supplier. BioDelivery submitted a product specification change...
08:00 , Dec 22, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Sep 15, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

Bunavail regulatory update

BioDelivery said FDA approved an NDA for Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence. The application was submitted under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference...
07:00 , Jun 16, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioDelivery Sciences International Inc. (NASDAQ:BDSI) gained $2.36 (24%) to $12.36 last week after FDA approved Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence. BioDelivery said it plans to launch the product late...
00:09 , Jun 10, 2014 |  BC Extra  |  Company News

FDA approves BioDelivery's Bunavail

BioDelivery Sciences International Inc. (NASDAQ:BDSI) said FDA approved Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence. The company said it plans to launch the product late next quarter, but has not yet finalized the...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

BioDelivery, Quintiles, Ashfield Market Access LLC sales and marketing update

Quintiles will provide a "competitively sized" field sales force to support the U.S. commercialization of BioDelivery's Bunavail buprenorphine naloxone to treat opioid dependence. Separately, BioDelivery entered into an agreement with payer strategy company Ashfield to...